A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.
On February 20, 2026, an expert panel under Japan's Health, Labor and Welfare Ministry approved the manufacture and sale of two induced pluripotent stem (iPS) cell-derived regenerative medicine products on a conditional and time-limited basis. These include Amchepry, a nerve cell product for Parkinson's disease developed by Sumitomo Pharma in partnership with Kyoto University, and a cardiomyocyte patch for severe heart failure developed by Cuorips Inc. from Osaka University.
Parkinson's disease, caused by a decline in dopamine-producing brain neurons, affects an estimated 250,000 people in Japan with symptoms like tremors and walking difficulties. In clinical trials at Kyoto University, iPS-derived nerve cells transplanted into the brains of six patients produced dopamine in all cases, with four showing clinical improvements in motor function. Results included enabling a patient who needed assistance to walk to live independently, outcomes not achieved by conventional methods.
The heart patch targets ischemic cardiomyopathy, where heart function deteriorates due to arteriosclerosis or heart attacks, potentially benefiting 3,000 patients in Japan. In Osaka University's trials on eight participants, exercise function indicators improved in four.
Kyoto University Emeritus Professor Shinya Yamanaka, who won the 2012 Nobel Prize for iPS cell research, stated: “I am very happy to have taken a major step forward at this 20-year milestone since the debut of iPS cells. However, to establish this as a medical treatment, a process to confirm safety and efficacy in more cases is essential.” Kyoto University's Professor Atsushi Takahashi, director of the Center for iPS Cell Research and Application, said: “The result of our deliberations is a major step forward. We will make every effort to ensure these treatment methods become common options that are fully trusted as soon as possible.”
The approval is conditional: companies must gather post-market data on safety and efficacy and reapply for full approval within seven years, expanding from small trials to dozens of cases. Failure to demonstrate efficacy could halt production and sales. A previous example is a 2015 conditionally approved heart treatment using thigh muscle cells, based on seven cases, whose approval was suspended in 2024 after failing to meet requirements despite a three-year extension.
Regenerative products are costly due to cell cultivation and quality control; a similar thigh muscle patch cost ¥14.76 million, partially covered by insurance. Fujita Health University Professor Yoshimi Yashiro noted: “The fact that iPS cells, which didn’t exist on earth, have been commercialized in about 20 years is certainly a rapid development. Now that these first approvals have been issued, I think it’ll become easier for various companies to enter the sector and to attract more investment.” However, Arthur D. Little consultant Ryo Hanamura warned: “Prices will be the biggest focus of attention. If the price is too low from a business’ perspective, subsequent companies won’t enter the market.”
The government invested ¥110 billion in regenerative medicine research over 10 years from fiscal 2013. The world's first iPS cell transplant for an eye disease in 2014 showed no cancerous changes after 10 years, advancing confidence in the technology.
